By Thomas Lee
MINNEAPOLIS, Minnesota– Miromatrix Inc. has one official employee, zero money, and nothing yet to develop, never mind sell. But make no mistake: Everyone wants a piece of it.
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
By Thomas Lee
MINNEAPOLIS, Minnesota– Miromatrix Inc. has one official employee, zero money, and nothing yet to develop, never mind sell. But make no mistake: Everyone wants a piece of it.
Boston Scientific Corp. (NYSE:BSX) won the latest round in its long-running patent war with Johnson & Johnson (NYSE:JNJ) when a federal judge declared invalid a quartet of J&J subsidiary Cordis Corp’s. patents for drug-eluting stents.
The patents in question are at the heart of complicated legal wrangling involving the Natick, Mass.-based medical device giant, its new Brunswick, N.J.-based rival, Abbott (NYSE:ABT) and Wyeth. The dispute centers around Boston Scientific’s Promus stent, a private-label version of Abbott’s Xience V stent, and the Cordis Cypher.
A federal judge this week sided with Cordis and fellow plaintiff Wyeth, now part of Pfizer Inc. (NYSE:PFE), transfering a suit seeking to invalidate a patent co-owned by the two companies from the U.S. District Court for Minnesota to New Jersey. The suit was bought by Abbott Laboratories (NYSE:ABT) and Boston Scientific Corp. (NYSE:BSX) as part of their defense against a suit alleging the Xience V and Promus drug-eluting stents infringe on the Cypher stent made by Cordis.
A few of the biggest players in the medical devices arena are accused in a whistleblowers lawsuit of promoting the off-label use of biliary stents to treat cardiovascular disease in hundreds of thousands of patients.
Boston Scientific Corp. (NYSE:BSX) enrolled the first patient in a clinical trial of its WallFlex biliary stent for the treatment of benign bile duct strictures.
The Natick, Mass.-based medical device colossus said it plans to enroll 187 patients at 11 centers worldwide over the next 18 months for the trial, which will evaluate the removal of the stents from patients with benign bile duct strictures and the effectiveness of temporary stenting for long-term, benign biliary stricture resolution.
The U.S Supreme Court dashed Boston Scientific Corp.’s (NYSE:BSX) hopes of collecting damages from St. Jude Medical (NYSE:STJ) in a long-running patent infringement battle over pacemaker technology.
The Supremes declined to hear Boston Scientific’s appeal in the 14-year-old case, meaning a lower court’s decision barring BSX from collecting the damages will stand.
Abbott (NYSE:ABT) won approval from the Japanese Ministry of Health, Labor and Welfare for its Xience V drug-eluting stent.
Abbott said it plans to bring the device to market as soon as it receives final reimbursement authorization from Japanese officials.